Welcome to our dedicated page for Milestone Pharmaceuticals news (Ticker: MIST), a resource for investors and traders seeking the latest updates and insights on Milestone Pharmaceuticals stock.
Milestone Pharmaceuticals Inc. develops and commercializes cardiovascular medicines, centered on CARDAMYST (etripamil) nasal spray. CARDAMYST is FDA-approved for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia, or PSVT, to sinus rhythm in adults. Etripamil is also being developed for symptomatic episodic attacks associated with AFib-RVR.
Company news commonly covers CARDAMYST commercialization, payer formulary access, real-world evidence work such as the RESET-PSVT registry, cardiovascular conference presentations, regulatory updates, financial results and business updates. Milestone also reports equity inducement grants and other corporate actions tied to its Nasdaq-listed common shares.
Milestone Pharmaceuticals (Nasdaq: MIST) reported second quarter 2026 results and launch progress for CARDAMYST nasal spray for PSVT. More than 800 unique prescribers and over 1,500 scripts for >1,300 patients were recorded through June 30, up from ~200 prescribers and 300 scripts at Q1-end.
Commercial coverage for CARDAMYST expanded from ~25% of U.S. commercially insured lives during Q2 to over 50% to date, supported by new formulary decisions from major insurers. The Phase 3 ReVeRA-301 registrational trial in AFib-RVR is open with sites activated, targeting first patient enrollment in H2 2026. Regulatory review for etripamil in PSVT continues in Europe (EMA decision expected H1 2027) and China.
Cash, cash equivalents and short-term investments totaled $170.6 million as of June 30, 2026, versus $106.0 million at year-end 2025, with runway into H2 2027. Q2 2026 product revenue was $0.6 million, R&D expenses declined modestly year over year, and net loss widened to $28.6 million.
Milestone Pharmaceuticals (Nasdaq: MIST) will report its second quarter 2026 financial results, for the period ended June 30, 2026, on Wednesday, August 12, 2026, before the market opens. The company will host an investor conference call and webcast at 8:30am ET, with replay available via its website.
Milestone Pharmaceuticals (Nasdaq:MIST) granted a total of 288,000 stock options under its 2021 Inducement Plan as a material inducement for hiring six new employees, in line with Nasdaq Listing Rule 5635(c)(4).
The options, dated July 1, 2026, have a $1.32 exercise price and four-year vesting.
Alpha Cognition (Nasdaq: ACOG) elected Dr. Robert Wills as Chairman of the Board, succeeding retiring chair Len Mertz.
Dr. Wills has served on the board since 2025 and holds leadership roles at several biopharma companies, as Alpha Cognition advances ZUNVEYL’s commercial launch and its neurodegenerative pipeline.
Milestone Pharmaceuticals (Nasdaq:MIST) announced that management will present at the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ on May 19, 2026, in New York.
A live and replay webcast of the 3:00 p.m. ET fireside chat will be available on Milestone's website.
Milestone Pharmaceuticals (Nasdaq:MIST) reported first quarter 2026 results and a corporate update. CARDAMYST™ nasal spray for PSVT is ramping, with about 600 scripts for 560 patients and roughly 400 unique prescribers through April. Express Scripts added CARDAMYST to its national formularies, giving coverage to over 25% of commercially insured U.S. lives. The company initiated a Phase 3 registration trial of etripamil for AFib-RVR, with first patient enrollment expected in H2 2026, and advanced global expansion with an EMA MAA under review and a China NDA accepted. Q1 product revenue was $0.2 million. Cash, cash equivalents and short-term investments totaled $184.2 million, which Milestone expects will fund operations into H2 2027. Net loss was $26.1 million, or $0.20 per share.
Milestone Pharmaceuticals (Nasdaq: MIST) will report first quarter 2026 financial results on May 13, 2026 before the market open and will host a conference call and webcast at 8:30am ET.
Investor dial-in numbers, conference ID 13760062, and a webcast replay will be available on Milestone's website.
Milestone (Nasdaq: MIST) announced RESET-PSVT, a planned Phase 4, multicenter, prospective, observational registry to generate real-world evidence on CARDAMYST (etripamil) nasal spray in adults with paroxysmal supraventricular tachycardia (PSVT).
The registry, led by the Duke Clinical Research Institute, aims to enroll an estimated 450 patients across ~20 sites, with enrollment beginning by the end of 2026. Primary and secondary endpoints include patterns of use, episode frequency, doses per episode, patient-reported quality of life and healthcare utilization. CARDAMYST received FDA approval in December 2025 and is commercially available in the United States.
Milestone Pharmaceuticals (Nasdaq: MIST) will present at the 25th Annual Needham Virtual Healthcare Conference April 13–16, 2026. Management's webcast is scheduled for April 13, 2026 at 3:45 PM EDT.
According to the company, the presentation webcast will be available April 13 with a replay accessible for approximately 90 days on Milestone's News & Events page. Investors seeking meetings should contact their Needham representative.
Milestone Pharmaceuticals (Nasdaq: MIST) granted a total of 123,000 stock options under its 2021 Inducement Plan as material inducements for three new hires. The options were granted with an April 1, 2026 grant date and an exercise price of $1.31, equal to the closing share price on that date. The options vest over four years (25% after one year, then monthly over 36 months) and are subject to continuous service and the Plan's terms pursuant to Nasdaq Listing Rule 5635(c)(4).